RxDoctor Payments Data

Jennifer Rose-Nussbaumer, MD

Cornea and External Diseases Specialist · Stanford, CANPI 1598912859

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 21 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Alcon at 57.7% of the total. That places this record below the midpoint for cornea and external diseases specialist clinicians in CA, where the typical reported total is $4,024.

$1,639in general payments, 2019–2025

Across 21 payments — averaging $78.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$946
  • Johnson & Johnson Surgical Vision, Inc.$265
  • Carl Zeiss Meditec, Inc.$150
  • Genentech, Inc.$144
  • Rxsight Inc$135

What the payments were for

  • Food & beverage$1,639100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,639 in reported general payments places this provider in the 25th percentile of 50 cornea and external diseases specialist providers in California.

See all cornea and external diseases specialist providers in California

Medicare billing

Part B allowed, 2024
$123,725
Medicare patients
263
Services billed
960

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine13$9,188
XiidraLifitegrast11$7,577
Prednisolone Acetate134$7,427
ValacyclovirValacyclovir Hcl51$5,035
Cyclosporine19$4,003
RhopressaNetarsudil Mesylate12$3,396
Dexamethasone Sodium Phosphate80$3,138
Fluorometholone19$1,725
MoxifloxacinMoxifloxacin Hcl48$1,180
Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim60$477
Ketorolac Tromethamine11$306
Latanoprost19$302
Doxycycline Hyclate17$275
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat20$201

Paid to pharmacies, not to this prescriber.

Other cornea and external diseases specialist in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →